Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma
Status:
Completed
Trial end date:
2018-03-07
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well bevacizumab given with capecitabine and oxaliplatin work
in treating participants with small bowel or ampulla of Vater adenocarcinoma that has spread
to other places in the body. Monoclonal antibodies, such as bevacizumab, may interfere with
the ability of tumor cells to grow and spread. Drugs using in chemotherapy, such as
capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving bevacizumab, capecitabine, and oxaliplatin may work better in treating
participants with small intestinal or ampulla of Vater adenocarcinoma.